Novo Nordisk rebrands as 'Novo' and announces cultural strategy shift
Danish pharmaceutical company Novo Nordisk has announced a name change to simply 'Novo' for day-to-day use, while retaining its legal name. The move is part of a broader effort to redefine the company's culture under a new framework called 'The Novo Way,' emphasizing customer focus, competitiveness, clarity, and integrity. This rebranding comes amid intense competition in the obesity drug market from companies like Eli Lilly and pressure from investors for blockbuster results. Despite outperforming rivals in prescription numbers with its oral GLP-1 medication, Novo Nordisk has faced setbacks including the cancellation of late-stage trials for an experimental heart drug. The company plans to reveal more details about its business strategy during a Capital Markets Day on September 21.
Tickers: $LLY
Topics: competition corporate culture pharmaceuticals rebranding